Novartis
-
Potential losses exceed $300 billion! Nearly 200 drugs are facing a patent cliff
For more reports, please follow DrugTimes
-
Split! Sanofi may book $16.4 billion
For more reports, please follow DrugTimes. Many thanks!
-
【Weekly Headline News】August 26~September 1, 2024 (Updated in real time~~ Chinese version also updated~~)
Carefully selected industry hot news! Synchronized push in Chinese and English! Has your c…
-
Former Pfizer employees bravely venture into the red ocean of obesity drugs
Ambrosia, like Pfizer, is optimistic about the direction of oral small molecules, but whether it can surpass the front runners is something that still needs more time to verify
-
TOP PHARMAS BY 2024 PIPELINE SIZE
For more info, please visit https://www.drugtimes.cn/english-content
-
SMA领域硝烟再起，谁将杀出重围？谁将笑到最后？
2020年8月7日，美国FDA批准罗氏旗下基因泰克的Evrysdi（Risplam）用于治疗两个月及以上患有脊髓性肌萎缩症(SMA)的患者。而这次的批准，为患者带去了更为方便的给药…
-
梅开二度！生物制药巨头再生元与基因编辑新贵Intellia再次联手，共同研制血友病药物
欢迎参加2020中国NASH大会！ 美国时间2020年6月1日，生物制药领域再度传来合作的好消息。基因编辑新贵Intellia公司宣布将与生物制药巨头公司再生元（Regeneron…
